Press Releases
-
May 14, 2020Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter
Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
-
May 14, 2020
Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
-
May 12, 2020
Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
-
May 4, 2020
Salt Lake City, Utah – May 4, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
-
May 1, 2020
Salt Lake City, Utah – May 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
COMPANY
LATEST NEWS RELEASE
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.